High-dose Treatment with Neuroleptics in the Acute Phase of Mental Disease by Dr Sven J Dencker (Lillhagen Hospital, Gothenburg, Sweden) A series of empirical data (Dencker & Malm 1970 , Rifkin et al. 1971 , Sainsbury 1969 ) as well as controlled trials (Prien & Cole 1968 ) have shown that certain patients demand higher or much higher doses of neuroleptic drugs for clinical response than others. The usual strategy is to increase the amount of the drug slowly with regard to effect on target symptoms as well as side-effects. With a successive increase of neuroleptic dose, sooner or later extrapyramidal sideeffects will occur. The lower limit for such symptoms is individual and varies, furthermore, from one neuroleptic drug to another.
If, on the other hand, a high dose is given from the beginning, no extrapyramidal side-effects may occur. There seems to be not only a lower limit for parkinsonian symptoms but also a higher one. This will be discussed later with regard to the blood level of the neuroleptic drug. difference between what I would call the 'titration' and the 'high-dose treatment' approach. The latter is characterized by a short initial period when a high dose is given either as a single dose or as quickly repeated smaller doses. Definition ofHigh-dose Treatment I define high-dose treatment as the dose which is about 10 times larger than the usual maintenance dose. This implies in our present material 50 mg or more of haloperidol and 40 'mg or more of flupenthixol in a single dose; or 250 mg and 1000 mg of fluphenazine enanthate and perphenazine enanthate respectively. This definition is obviously subjective.
About seven years' experience with high-dose treatment has taught us that extrapyramidal complications or insufficient effect on psychotic symptoms may occur if we give one third lower dose than those mentioned in severe cases. The reported high doses must sometimes be repeated several times before the desired clinical effect is achieved.
Choice of Drug When using high doses of neuroleptics we particularly want two effects: the antipsychotic and the DAYS sedative. In recent years we have mainly used the following four neuroleptics in high dose: (1) ps) and flupenthixol orally; (2) haloperidol intravenously; 'darea (3) fluphenazine enanthate intramuscularly and (4) perphenazine enanthate intramuscularly.
Haloperidol: A New Profile.:'
We have used flupenthixol orally in solution. It has antipsychotic as well as sedative effects in single doses of 40 mg or higher. Haloperidol has initially been used intravenously and on the first occasion we give a dose of 50 mg, injected slowly over approximately five minutes. In 12 of 16 cases we have noted sedation and possibly sleep during two to three hours after the injection. When this dose has not given the desired effect, we have given on the same day a further intravenous dose of 50-100 mg. In two cases the treatment has been continued with 50 and 100 mg respectively, in solutions given orally at night.
Fluphenazine and perphenazine, both in the enanthate form given intramuscularly, are depot neuroleptics. Apart from increased sleep the night after the injection, fluphenazine enanthate is not usually followed by sedation even at a dose of 250 mg or higher. However, we rather commonly notice the sedative effect of perphenazine enanthate in doses of 1000 mg or more.
As far as possible we use only one drug but have sometimes combined them, especially if sedation has been required together with an antipsychotic effect. Chlorpromazine, chlormethiazole or a benzodiazepine in normal doses have been added for sedation. Flupenthixol and haloperidol in the high doses presented here have an antipsychotic effect lasting one to three days. Fluphenazine and perphenazine enanthate have an antipsychotic effect with a duration of up to two weeks or longer.
Relevant Patients
All patients receiving neuroleptics in high doses have been treated in our intensive care unit of 10 beds in a department of 300 beds and two daypatient wards. The admission rate per year is 2500. The patients vary from alcoholics and drug addicts with severe withdrawal syndromes to psychotics of both the acute and the chronic type. Among the men, alcoholics are in the majority, whilst the women show a more varied profile of neurotic and psychotic states.
The number of patients receiving high doses of neuroleptics during the last three years is as follows: flupenthixol, 51 patients; haloperidol, 16; fluphenazine enanthate, 156; and perphenazine enanthate, 72. Haloperidol in high dose has only been used for six weekshence the relatively small number of cases. If we correct the figures with regard to patients independently getting one 'or more neuroleptics in high doses we reach a total figure of 270. This means that approximately one patient out of 25 admissions has been treated with high doses of neuroleptics in our department.
We have occasionally treated patients aged 65-70 years but have always carefully selected those without somatic diseases. Such patients have only exceptionally been given high doses of neuroleptics, which may be the reason why we have not seen any severe somatic complications except extrapyramidal symptoms. The main group of treated patients are alcoholics with severe withdrawal syndromes including psychotic states; schizophrenics with relapses and patients in an acute psychotic phase.
What Happens in High-dose Treatment with Neuroleptics? Fig 2 shows schematically what happens when we give a neuroleptic with a short half-life in high dose. The clinical effect can be observed even during the intravenous injection or within 0.5 hours if the drug is given by mouth. Determinations of haloperidol levels in blood (A 0 Forsman 1975, personal communication) have shown high initial values after intravenous administration. The values fall after a few hours, proceeding to a slower beta-slope. So long as we find the very high initial values in blood the patient usually shows signs of sedation and sometimes falls asleep. With values corresponding to the extrapyramidal area, the sedation has disappeared completely. (Larsen & Naestoft 1973) . In as little as half an hour after the intramuscular injection (usually given in various muscle sites) we can show maximum values in the blood. Thus we find an association between the observed and rapidly established antipsychotic effect and an initially high blood level of the drug. With these depot neuroleptics we then have a persistent high blood level of the drug, which usually remains as a plateau for at least three to five days and then usually falls, but still remains much higher than if conventional doses had been used.
The blood level of neuroleptics with shorter as well as longer half-lives apparently rises so quickly when given in high doses that no (or only slight) extrapyramidal side-effects appear. When the blood level is eventually reduced (and here apparently the duration of the dose does not play any important part) extrapyramidal side-effects do not occur regularly. When they do they are usually only in a mild form in spite of the blood level apparently being in the so called 'extrapyramidal risk zone' for several days. We have no explanation for this. It may possibly depend on the patient being able to adapt his dopaminergic nerve system to the pharmacological situation. It must, however, be noted that we do sometimes see patients with severe extrapyramidal symptoms during this late phase.
We usually treat acute psychotic states of a limited duration with a depot neuroleptic at a high dose. Thus we use in combination a rapid initial antipsychotic effect with an extended duration of neuroleptic therapy of one to three weeks. In other cases we have combined a longacting drug with some orally or parenterally added neuroleptic having a shorter half-life. We have thus used our depot neuroleptic as some form of pharmacological base and added a more short-lasting neuroleptic drug for guidance of the treatment process.
In several cases with the more short-acting flupenthixol and haloperidol we have sometimes seen a clinical effect which after a single dose has remained for some days and which can be sufficient in these cases. Haloperidol in intravenous form was given in 16 cases. In 6 we considered the effect good; in a further 6 relatively good; and in the remaining 4 cases the effect was negligible or uncertain. Two patients, both alcoholics with an earlier history of epilepsy, had fits 10-15 minutes after the injection. One of those patients, who normally had a series of fits, on this occasion had only a single attack. The day after the injection three patients had mild extrapyramidal side-effects which quickly disappeared.
Summary
More than 300 patients have been observed during treatment with either flupenthixol, haloperidol, fluphenazine enanthate or perphenazine enanthate in high doses, whilst suffering from severe mental disease, usually of psychotic nature. Used correctly, high-dose treatment gives a rapid control of psychotic symptoms, an earlier discharge from the ward, and (when using longacting neuroleptics) pharmacological control even during a follow up period. This means a social availability gain of 30-50%. We have not seen any severe somatic effects except those of parkinsonian type which can be treated successfully by the well trained psychiatrist and a skilled staff.
